Jiangsu Recbio Technology Co., Ltd.
HKSE 2179.HK
Jiangsu Recbio Technology Co., Ltd. Price to Sales Ratio (P/S) on January 13, 2025: 119.86
-
Jiangsu Recbio Technology Co., Ltd. 52-week high Price to Sales Ratio (P/S) is 142.22 on March 27, 2024, which is 18.65% above the current Price to Sales Ratio (P/S).
-
Jiangsu Recbio Technology Co., Ltd. 52-week low Price to Sales Ratio (P/S) is 107.57 on October 02, 2024, which is -10.26% below the current Price to Sales Ratio (P/S).
-
Jiangsu Recbio Technology Co., Ltd. average Price to Sales Ratio (P/S) for the last 52 weeks is 124.98.
| Date | Price to Sales Ratio (P/S) | Price to Book Ratio (P/B) | Dividend Yield | Free Cash Flow Yield |
|---|
| CEO | Dr. Yong Liu |
| IPO Date | March 31, 2022 |
| Location | China |
| Headquarters | No. 888 Yaocheng Avenue |
| Employees | 507 |
| Sector | Health Care |
| Industries | |
Jiangsu Recbio Technology Co., Ltd., a vaccine company, engages in the research, development, and commercialization of subunit vaccines in the People's Republic of China. The company is developing vaccines for the treatment of cervical cancer and genital warts, including REC603, a recombinant human papillomavirus (HPV) 9-valent vaccine that is in phase III clinical trial; REC601 and REC602 recombinant HPV bivalent vaccines, which are in phase I clinical trials; REC604a, a recombinant HPV quadrivalent vaccine that is in pre-clinical stage; and REC604b, a recombinant HPV 9-valent vaccine that is in pre-clinical stage. It is also developing ReCOV, a recombinant COVID-19 vaccine candidate that is in Phase II/III trial; and R520A, a messenger ribonucleic acid COVID-19 vaccine candidate that is in pre-clinical stage; REC610, a recombinant shingles vaccine that is in pre-clinical stage; REC607, a virus vectored adult tuberculosis vaccine that is in pre-clinical stage; REC606, a recombinant adult tuberculosis vaccine that is in pre-clinical stage; REC617, a recombinant influenza quadrivalent vaccine that is in pre-clinical stage; and REC605, a recombinant hand-foot-mouth disease quadrivalent vaccine that is in pre-clinical stage. The company was founded in 2011 and is based in Taizhou, the People's Republic of China.
Past 5 years
USD 3.69
USD 0.20
USD 0.31
StockViz Staff
January 15, 2025
Any question? Send us an email